SPP1 and metabolic dysfunction-associated steatohepatitis: With the knowledge that ResKCs have been suggested to be protective in NASH (Tran et al., 2020), our data suggesting a lack of ResKCs in HCC and the finding that osteopontin expression correlates with worse disease (Glass et al., 2018), perhaps if we can understand the signals driving ResKC loss and LAM generation in MAFLD, this could open the door to therapeutic options for patients to prevent and/or reverse progression to NASH and HCC.